SIM
AKRO

Sandia Investment Management’s Akero Therapeutics AKRO Stock Holding History

Sandia Investment Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,000
Closed -$170K – 241
2022
Q3 		$170K Buy
+5,000
New +$76.5K 0.03% 175

Other funds holding AKRO

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sandia Investment Management's AKRO Position: Q4 2022 in Review

Sandia Investment Management sold out of Akero Therapeutics (AKRO) in Q4 2022, closing a stake of 5,000 shares — an estimated $170K sold.

Sandia Investment Management first reported a position in AKRO in Q3 2022 and held it in 1 quarter. The position peaked at $170K in Q3 2022. 162 funds tracked by Wall St. Rank hold AKRO as of Q4 2022.

  • Sandia Investment Management reported no remaining Akero Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Sandia Investment Management sold 5,000 Akero Therapeutics shares in Q4 2022, an estimated $170K.
  • Sandia Investment Management first reported a position in Akero Therapeutics in Q3 2022 and held it in 1 quarter.
  • Sandia Investment Management's Akero Therapeutics position peaked at $170K in Q3 2022.
  • 162 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2022.

Based on Sandia Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.